2.50
Hdl Handle:
http://hdl.handle.net/10541/81235
Title:
Tamoxifen ("Nolvadex"): a review.
Authors:
Clemons, Mark; Danson, Sarah; Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Tamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women.It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors.
Affiliation:
Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. mark.clemons@tsrcc.on.ca
Citation:
Tamoxifen ("Nolvadex"): a review. 2002, 28 (4):165-80 Cancer Treat. Rev.
Journal:
Cancer Treatment Reviews
Issue Date:
Aug-2002
URI:
http://hdl.handle.net/10541/81235
PubMed ID:
12363457
Type:
Article
Language:
en
ISSN:
0305-7372
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorClemons, Mark-
dc.contributor.authorDanson, Sarah-
dc.contributor.authorHowell, Anthony-
dc.date.accessioned2009-09-16T10:06:37Z-
dc.date.available2009-09-16T10:06:37Z-
dc.date.issued2002-08-
dc.identifier.citationTamoxifen ("Nolvadex"): a review. 2002, 28 (4):165-80 Cancer Treat. Rev.en
dc.identifier.issn0305-7372-
dc.identifier.pmid12363457-
dc.identifier.urihttp://hdl.handle.net/10541/81235-
dc.description.abstractTamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women.It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Antagonistsen
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAromatase Inhibitors-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCarcinoma, Intraductal, Noninfiltrating-
dc.subject.meshDrug Resistance, Neoplasm-
dc.subject.meshEnzyme Inhibitors-
dc.subject.meshEstrogen Antagonists-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshTamoxifen-
dc.titleTamoxifen ("Nolvadex"): a review.en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. mark.clemons@tsrcc.on.caen
dc.identifier.journalCancer Treatment Reviewsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.